Pricing Log in Create free account

Liminatus Pharma Inc. (LIMN) vs Lunai Bioworks Inc. (LNAI)

Liminatus Pharma Inc. and Lunai Bioworks Inc. are both Biotechnology companies. Liminatus Pharma Inc. and Lunai Bioworks Inc. are of similar size ($4.3M and $4.2M). Liminatus Pharma Inc. has the higher net margin (0.00% vs −3,761.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, Liminatus Pharma Inc. leads on 7 and Lunai Bioworks Inc. on 4.

Valuation

Metric LIMN LNAI Biotechnology median
P/E n/m n/m 8.50
P/S n/m 24.13 9.71
P/B 9.79 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 18.71 9.21
Earnings yield (773.03%) (150.78%) (33.15%)
Free cash flow yield (135.00%) (232.47%) (25.50%)

Profitability

Metric LIMN LNAI Biotechnology median
Gross margin — (3.48%) 65.16%
Operating margin 0.00% (9,184.79%) 0.00%
Net margin 0.00% (3,761.88%) 0.00%
Free cash flow margin 0.00% (5,610.24%) 0.00%
Return on equity 294.43% 23.46% (56.36%)
Return on assets (471.47%) (39.21%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric LIMN LNAI Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) (112.19%) 98.77% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric LIMN LNAI Biotechnology median
Debt to equity 4.80 0.00 0.00
Current ratio 1.12 0.11 4.72
Net debt to EBITDA (0.37) 0.20 0.96

Dividend

Metric LIMN LNAI Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric LIMN LNAI Biotechnology median
Market cap 4.32m 4.15m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack